Short Summary
Lenovo’s request for Director Review of the PTAB’s denial to institute its IPR against Intellectual Ventures was rejected. The denial leaves the institution decision unchanged.
Detailed Summary
In IPR2024-01224, Lenovo sought a Director Review of the PTAB’s earlier decision that denied institution of an inter partes review against Intellectual Ventures’ U.S. Patent No. 7,623,439. After reviewing the petition and the patent owner’s response, the Director concluded that the request did not satisfy the statutory standards for overturning the institution denial and ordered the request denied. Consequently, the institution denial remains in effect, and the IPR will not proceed.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in LENOVO (UNITED STATES) INC. et al. vs Intellectual Ventures I LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Samsung Electronics Co., Ltd. et al.vsHeadwater Research LLC
Samsung filed an authorized response opposing Headwater’s request for Director Review of the Board’s institution of IPR2024‑01407. Samsung contends the institution was proper, based on prior‑art disclosures and a correct Fintiv analysis, and that Headwater’s alleged prejudice is unfounded.
PacifiCorp et al.vsMES, Inc.
MidAmerican Energy Company and BirchTech Corp. have settled their dispute over U.S. Patent No. 10,933,370 and filed a joint motion to terminate the inter partes review proceeding as to MidAmerican.
Mercedes-Benz Group AG et al.vsPhelan Group, LLC
Mercedes‑Benz has filed an IPR petition seeking cancellation of all 14 claims of the Phelan Group’s driver‑authentication patent, alleging anticipation and obviousness over multiple prior‑art references.
Tessell, Inc.vsNutanix, Inc.
Tessell, Inc. has filed a Request for Director Review seeking reversal of the PTAB Director’s denial of institution for its IPR against Nutanix’s patent 10,817,157. The petition argues the Director exceeded authority under 35 U.S.C. §314(a) by applying assignor estoppel, which Federal Circuit precedent bars in IPRs.
Padagis US LLC et al.vsNeurelis, Inc.
The PTAB held that all 36 claims of Neurelis’s intranasal benzodiazepine patent are obvious over prior art references Gwozdz, Meezan ’962, and Cartt ’784, rendering the patent entirely unpatentable.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.